Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)
70.26
+0.89 (1.28%)
May 8, 2026, 3:04 PM CST
SHE:300573 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 574.03 | 393.71 | 370.12 | 480.42 | 515.45 | 686.36 |
Cash & Short-Term Investments | 574.03 | 393.71 | 370.12 | 480.42 | 515.45 | 686.36 |
Cash Growth | 13.63% | 6.37% | -22.96% | -6.80% | -24.90% | 1744.12% |
Accounts Receivable | 317.64 | 325.92 | 277.93 | 252.1 | 194.96 | 170.62 |
Other Receivables | 2.78 | 2.09 | 3.37 | 3.93 | 4.62 | 5.84 |
Receivables | 320.42 | 328.02 | 281.3 | 256.03 | 199.58 | 176.46 |
Inventory | 215.47 | 189.23 | 153.6 | 136.03 | 122.27 | 92.33 |
Other Current Assets | 22.81 | 19.78 | 24.9 | 32.71 | 27.87 | 29.27 |
Total Current Assets | 1,133 | 930.73 | 829.92 | 905.19 | 865.17 | 984.42 |
Property, Plant & Equipment | 1,302 | 1,301 | 992.22 | 837.35 | 695.92 | 548.6 |
Long-Term Investments | 11.67 | 11.67 | 10 | - | - | - |
Other Intangible Assets | 217.79 | 222.62 | 134.57 | 78.29 | 27.66 | 22.83 |
Long-Term Deferred Tax Assets | 20.18 | 19.68 | 22.5 | 38.57 | 23.77 | 30.45 |
Long-Term Deferred Charges | 2.76 | 3.4 | 64.44 | 118.76 | 105.03 | 60.77 |
Other Long-Term Assets | 61.8 | 50.01 | 74 | 45.68 | 65.39 | 39.78 |
Total Assets | 2,749 | 2,539 | 2,128 | 2,024 | 1,783 | 1,687 |
Accounts Payable | 49.42 | 35.49 | 17.73 | 17.57 | 19.46 | 13.31 |
Accrued Expenses | 92.97 | 218.16 | 178.33 | 125.36 | 103.97 | 108.91 |
Short-Term Debt | 70.05 | 70.05 | 200.17 | 70.06 | - | 100 |
Current Portion of Leases | 7.43 | 7.6 | 6.28 | 6.87 | 7.12 | 4.18 |
Current Income Taxes Payable | 75.05 | 56.3 | 22.84 | 5.74 | - | 11.69 |
Current Unearned Revenue | 3.34 | 1.88 | 3.46 | 6.76 | 2.01 | 6.11 |
Other Current Liabilities | 208.69 | 111.34 | 32.67 | 27.76 | 19.89 | 22.63 |
Total Current Liabilities | 506.95 | 500.83 | 461.48 | 260.12 | 152.45 | 266.83 |
Long-Term Leases | 3.46 | 4.38 | 8.86 | 2.22 | 6.69 | 7.1 |
Long-Term Unearned Revenue | 53.4 | 55.72 | 64.13 | 71.58 | 71.5 | 68.42 |
Total Liabilities | 563.82 | 560.93 | 534.48 | 333.92 | 230.63 | 342.35 |
Common Stock | 246.43 | 246.43 | 175.25 | 124.59 | 88.56 | 88.1 |
Additional Paid-In Capital | 830.58 | 829.93 | 866.51 | 891.01 | 852.36 | 782.68 |
Retained Earnings | 1,107 | 900.27 | 551.4 | 674.32 | 611.4 | 479 |
Treasury Stock | - | - | - | - | - | -5.28 |
Comprehensive Income & Other | 1.42 | 1.42 | - | - | - | - |
Total Common Equity | 2,185 | 1,978 | 1,593 | 1,690 | 1,552 | 1,344 |
Shareholders' Equity | 2,185 | 1,978 | 1,593 | 1,690 | 1,552 | 1,344 |
Total Liabilities & Equity | 2,749 | 2,539 | 2,128 | 2,024 | 1,783 | 1,687 |
Total Debt | 80.94 | 82.03 | 215.31 | 79.15 | 13.81 | 111.28 |
Net Cash (Debt) | 493.09 | 311.69 | 154.81 | 401.27 | 501.64 | 575.08 |
Net Cash Growth | 60.52% | 101.33% | -61.42% | -20.01% | -12.77% | - |
Net Cash Per Share | 2.01 | 1.27 | 0.63 | 1.65 | 2.08 | 2.56 |
Filing Date Shares Outstanding | 246.43 | 246.43 | 245.35 | 244.19 | 243 | 241.74 |
Total Common Shares Outstanding | 246.43 | 246.43 | 245.35 | 244.19 | 243 | 241.74 |
Working Capital | 625.78 | 429.9 | 368.44 | 645.07 | 712.72 | 717.59 |
Book Value Per Share | 8.87 | 8.03 | 6.49 | 6.92 | 6.39 | 5.56 |
Tangible Book Value | 1,967 | 1,755 | 1,459 | 1,612 | 1,525 | 1,322 |
Tangible Book Value Per Share | 7.98 | 7.12 | 5.94 | 6.60 | 6.27 | 5.47 |
Buildings | - | 528.48 | 517.5 | 476.93 | 470.69 | 350.19 |
Machinery | - | 964.78 | 759.99 | 711.75 | 534.35 | 481.36 |
Construction In Progress | - | 380.26 | 196.85 | 106.16 | 70.12 | 34.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.